Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.
Saved in:
| Title: | Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study. |
|---|---|
| Authors: | Manzi S; Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania., Bruce IN; Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom.; Centre for Public Health, Faculty of Medicine, Health, and Life Sciences, Queen's University Belfast, Belfast, United Kingdom., Morand EF; Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia., Furie R; Division of Rheumatology, Northwell, Great Neck, New York., Tanaka Y; Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan., Kalunian KC; Lupus Center of Excellence, Division of Rheumatology, Autoimmunity, and Inflammation, University of California, San Diego School of Medicine, La Jolla, California., Askanase A; Division of Rheumatology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York., Puzio P; BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland., Khan E; BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom., Wissmar J; BioPharmaceuticals R&D, Late-Stage Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden., Song M; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, Massachusetts., Lindholm C; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden. |
| Corporate Authors: | TULIP‐SC investigators |
| Source: | Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2026 Jun; Vol. 78 (6), pp. 1258-1267. Date of Electronic Publication: 2026 Feb 17. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
